Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial

NCT04398004 is registered in ClinicalTrials.gov with Hellenic Institute for the Study of Sepsis as lead sponsor.

NCT NCT04398004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04398004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial
Lead sponsor
Hellenic Institute for the Study of Sepsis
Phase
Phase 2
Overall status
Completed
Start date
May 6, 2020
Completion date
November 30, 2020
Enrollment
90 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, covid-19, virus diseases